US20120071767A1 - Pulmonary artery pressure estimator - Google Patents
Pulmonary artery pressure estimator Download PDFInfo
- Publication number
- US20120071767A1 US20120071767A1 US13/053,202 US201113053202A US2012071767A1 US 20120071767 A1 US20120071767 A1 US 20120071767A1 US 201113053202 A US201113053202 A US 201113053202A US 2012071767 A1 US2012071767 A1 US 2012071767A1
- Authority
- US
- United States
- Prior art keywords
- component
- interval
- heart
- sound
- sensors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B7/00—Instruments for auscultation
- A61B7/02—Stethoscopes
- A61B7/04—Electric stethoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
Definitions
- non-invasive heart diagnostics is based upon auscultation and a physician's ability to use a stethoscope to recognize specific patterns and phenomena. Through advances in technology, many of these abilities have been automated. For some of these auscultation methods, however, a stable automated procedure has yet to be found.
- Pulmonary artery hypertension is caused by several heart or pulmonary diseases including dysfunction of prosthetic or native heart valves, left ventricular dysfunction, congenital abnormalities of the heart and great vessels, chronic obstructive pulmonary disease, and adult respiratory distress syndrome. Pulmonary artery hypertension is a serious cardiovascular dysfunction that is difficult to assess non-invasively.
- the pulmonary artery pressure (PAP) is usually measured using a pulmonary arterial catheter. This is an invasive surgical procedure that is associated with significant morbidity and modality.
- a pulmonary arterial catheter can be left in place for a few days to allow continuous monitoring of PAP of patients in the critical care unit.
- catheterization is not recommended for repeated measurements. Nonetheless, regular evaluation of the PAP is very important to identify pulmonary hypertension and subsequently to follow the evolution of the disease and to assess the efficacy of treatment. Consequently, the development of non-invasive methods that allow frequent and accurate measurement of PAP are particularly advantageous.
- Doppler echocardiography is one non-invasive method that can be used to estimate the systolic PAP. If tricuspid regurgitation is detected, it is possible to estimate the systolic pressure gradient across the tricuspid valve using continuous-wave Doppler. The right ventricular systolic pressure can be calculated by sliding the systolic tricuspid valve gradient to the estimated right atrial pressure. The right ventricular systolic pressure can be considered equivalent to the systolic PAP when the systolic pressure gradient across the pulmonary valve is negligible.
- This noninvasive method can provide a high degree of correlation (0.89 ⁇ r ⁇ 0.97) and a standard error estimate (SEE) varying from 7 to 12 mmHg with pulmonary artery catheterization (for systolic PAP range: 20-180 mmHg).
- SEE standard error estimate
- the estimation of PAP by Doppler echocardiography has several important limitations.
- PAP cannot be estimated by Doppler in approximately 50% of patients with normal PAP, 10 to 20% of patients with elevated PAP and 34 to 76% of patients with chronic obstructive pulmonary disease. This is due to the absence of tricuspid regurgitation, a weak Doppler signal or a poor signal-to-noise ratio.
- Doppler echocardiography tends to overestimate PAP in patients with normal PAP and significantly underestimate the PAP in patients with severe pulmonary arterial hypertension.
- a PAP estimation method is based on the spectral properties of the P2 component of the second heart sound.
- the basic principle supporting this approach is based on Laplace's Law and assumes that the tension of the pulmonary wall is proportional to the corresponding intra-arterial blood pressure. Similar to a stretched drumhead, it is expected that the resonant frequency of the blood column in the pulmonary artery is proportional to the tension in the arterial wall and thus to the arterial pressure.
- Spectral methods have shown a high correlation between spectral features of P2 and the systolic PAP measured by PA catheterization. The two features were the dominant frequency and the quality factor of the spectrum of P2.
- systolic PAP estimated by Doppler echocardiography can be predicted from the spectral features extracted from P2.
- the second heart sound For diagnostic of cardiac events, one of the most interesting sounds is the second heart sound.
- This sound comprises two components which are generally of interest: the aortic component and the pulmonary component. Detection and recognition of those components provides the possibility of measuring the systole and diastole duration for both the left- and right heart. These values are very important for many applications such as detection of pulmonary artery hypertension, dysfunction of heart valves, left and right ventricular dysfunction, etc.
- the second heart sound and the components A2 and P2 thereof have significant clinical value.
- these components are very often masked by noises and other acoustic components of both the heart sounds and other parts of human body.
- typically only specially trained and experienced clinicians can distinguish the A2 and P2 components.
- an automated computer-based procedure for A2 and P2 components would be desirable in clinical practice.
- Cardiac catheterization and echocardiography which have provided an accurate diagnosis of both right- and left heart abnormalities, have added a new dimension to usefulness of the phonocardiogram in assessing the presence and severity of cardiovascular abnormalities.
- cardiac catheterization generally provides the decisive evidence of the presence and severity of cardiac abnormalities, the external sound recordings correlate sufficiently well with the internal findings for them to serve, in many instances, as diagnostic tool per se.
- phonocardiography often provides information complementary to that obtained by echocardiography. With this enhanced diagnostic accuracy, simpler and less painful external techniques can be used to determine when a patient needs more extensive cardiac treatment. Even in those cases where cardiac catheterization is deemed necessary, the knowledge gained beforehand through phonocardiography and other non-invasive studies can lead to much more efficient and fruitful invasive study.
- NAI normalized splitting interval
- S2 second heart sound
- A2 aortic
- P2 pulmonary
- the splitting interval is normalized by a cardiac interval (CI) derived from an ECG.
- CI cardiac interval
- the cardiac interval is derived from an average of intervals between a predetermined number of consecutive QRS waves of the ECG.
- a PAP estimator determines a location of pulmonary and aortic components of second heart sounds of a patient over an interval.
- the method comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, identifying at least one second heart sound in the interval using the electronic representation, for each identified second heart sound calculating a frequency weighted energy (FWE), normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component, and generating an estimated value for a location of the aortic component
- peaks having an amplitude of a predetermined value between 90% and 100% of the amplitude of the maximum peak are retained. Peaks having an amplitude less than a predetermined value between 90% and 100% of the amplitude of the maximum peak are discarded. Similarly, in an embodiment of this method, peaks are retained which have an amplitude lower than the amplitude of the maximum peak by a value between 0 and 10% of the amplitude of the maximum peak.
- the method comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, dividing the electronic representation into a plurality of sub-channels, for each of the sub-channel representations, identifying at least one second heart sound in the interval using the electronic representation and extracting an estimated location of a sub-channel aortic component and a sub-channel pulmonary component from the at least one second heart sound, combining the estimated sub-channel aortic component locations to form the estimated aortic component location and the estimated sub-channel pulmonary component locations to form the estimated pulmonary component location.
- a method for estimating a location of pulmonary and aortic components of second heart sounds a patient over an interval comprises the steps of positioning a first transducer at a first position on the patient, the first transducer producing a first electronic representation of heart sounds of the patient over the interval, positioning a second transducer at a second position on the patient, the second transducer producing a second electronic representation of heart sounds of the patient over the interval, for the first electronic representation identifying at least one second heart sound in the interval, for each identified second heart sound calculating a FWE, normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first
- a method for estimating pulmonary artery pressure of a patient over an interval comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, identifying at least one second heart sound in the interval using the electronic representation, for each identified second heart sound calculating a FWE, normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component and generating an estimated value for a location of an aortic component and a location of pulmonary component from the candidate values, determining a
- FIG. 1 is a general illustration of a pulmonary artery pressure (PAP) estimator embodiment
- FIG. 2 are graphs of typical signals detected by a PAP estimator embodiment
- FIG. 3 is a block diagram of a PAP estimator based upon a normalized splitting interval (SI).
- FIGS. 4A-B are flow charts of the A2, P2 and SI detection embodiments.
- FIG. 1 generally illustrates a pulmonary artery pressure (PAP) estimator embodiment 10 having two identical biological sound (acoustic) sensors 12 , for example those described in U.S. Pat. No. 6,661,161, incorporated by reference herein, are provided for, although in a given application a single sensor or more than two sensors may be preferable.
- sensors are placed at different locations on the patient 14 , where there is expected to be a maximal intensity of the aortic component of the second heart sound A2 or the pulmonary component of the second heart sound P2 or both A2 and P2 signals.
- one sensor 121 is positioned at the apex of heart, where the A2 component of the S2 sound is likely at its maximal in intensity and P2 component is minimal.
- a second sensor 122 is placed to maximize the P2 component intensity (between the 3rd and 4th left intercostal space). The best sensor locations are obtained by experimenting with different positions while observing S2 sound signals, so as to achieve the maximal signal intensity.
- the sensors 12 are attached via appropriate leads as in 16 to a data acquisition system 18 comprised of an analog to digital converter 20 and personal computer 22 .
- Data collected by the sensors 12 is digitized by the analog to digital converter 20 , illustratively using a sampling rate of 2 kHz with 12 bits of resolution.
- electrocardiogram (ECG) signals are also collected via a series of electrodes 24 , leads 26 and a second analog to digital converter 28 . Similar to the acoustic data collected by the biological sound sensors 12 , data collected by the ECG electrodes 24 is digitized by the analog to digital converter 28 , illustratively using a sampling rate of 2 kHz with 12 bits of resolution.
- the electrocardiogram is used as the reference signal to frame the second heart sound (S2).
- FIG. 2 illustrates typical signals detected by a PAP estimator embodiment, including an ECG reading displayed along side readings from first and second biological sound (acoustic) sensors.
- the ECG is used to provide the reference signal to frame the second heart sound.
- the ECG is also to determine a normalizing cardiac interval for the calculated splitting interval (SI).
- SI calculated splitting interval
- the beat signal in the description below means the part of acoustic signal between two consecutive QRS complexes on the ECG.
- the ‘beat signal” can be defined as the Q-Q’ (distance between two Q markers) or as the R-R′ (distance between two R markers).
- Q-Q′ provides the beat signal.
- the first heart signal S1 is detected and removed. The remaining sounds, including the second heart sounds and possibly murmurs and the like, are then used as input.
- FIG. 3 illustrates a pulmonary artery pressure (PAP) estimator 300 having acoustic sensor(s) 12 and ECG sensors 24 inputs.
- the acoustic sensor(s) 12 are used to measure second heart sounds 400 ( FIGS. 4A-B ) so that the data acquisition system 18 ( FIG. 1 ) derives a splitting interval (SI) 310 output.
- the ECG sensors 24 are used by the data acquisition system 18 ( FIG. 1 ) to frame the second heart sounds so as to derive S2 measurements 400 and to derive a cardiac interval (CI) 320 .
- CI 320 is based upon successive QRS intervals 300 of the ECG sensors 24 input.
- the data acquisition system 18 ( FIG. 1 ) utilizes CI to normalize SI 330 (NSI) so as to generate a PAP estimate 340 output.
- SI pulmonary artery pressure
- FIGS. 4A-B illustrate aortic component (A2), pulmonary component (P2) and splitting interval (SI) detection embodiments.
- the illustrative method supports input signals from the single or multiple sensor(s) 12 , each of them comprised of signals of heart sounds in the frequency range 30-200 Hz, although this range could be wider without any changes in the approach. If that range is narrower, however, the method should be adapted to those limitations.
- sounds related to heart beats are collected at 100 via a sensor(s) 12 and illustratively divided into three sub channels 102 , 104 and 106 (or frequency bands). These bands are: Low Frequency (LF, 30-50 Hz), Medium Frequency (MF, 50-150 Hz), and High Frequency (HF, 120-200 Hz).
- LF Low Frequency
- MF Medium Frequency
- HF High Frequency
- Each sub-channel is relayed to a “Process Channel” block as in 1081 , 1082 , and 1083 , (these will be described separately below).
- the process channel block can be based on a variety of methods including a Chirplet method, Nonlinear Energy Operator (NLEO) method, or any other suitable method capable of extracting and discriminating A2 and P2 components from second heart sound S2.
- NLEO Nonlinear Energy Operator
- the illustrated embodiment applies the NLEO method.
- the output values of A2 and P2 from the process channel blocks as in 1081 , 1082 , and 1083 are analyzed. If both components A2, P2 are clearly detectable in at least one of the sub channels, these are the values for A2, P2. If both components are not clearly detectable then the outputs of the process channel blocks as in 1081 , 1082 , and 1083 are compared sub-channel by sub-channel with the output of the process channel blocks for other sensors (not shown) of the same sub channels at blocks 110 , 112 , and 114 . In the case at hand, there are illustratively two sensors (the second sensor not shown) the outputs of the process blocks of which are thus compared pair wise.
- the comparison is carried out on each frequency band according to the following set of rules, although it should be understood that this is an example and not intended to be limiting. If the output of 108 for both sensors reveals A2 and P2 components and the positions of A2 and P2 in each sensor output are the same, then these positions provide the values of A2 and P2. If one of the outputs of 108 for both sensors reveals A2 and P2 components, but the other does not, then the positions of these A2 and P2 provide the values of A2 and P2.
- the output of 108 for both sensors reveals only one A2 or one P2 component then, as it is unknown whether the component is A2 or P2, then the value of A2 is the position of the first component and the value of P2 the position of the second component. If the output of 108 for one of the sensors reveals both A2 and P2 components while the output of 108 for the other sensor reveals only one (A2 or P2) component, then the readings for both sensors are combined (superimposed). If the result reveals only two components (A2 and P2) then the positions of these A2 and P2 provide the values of A2 and P2.
- the result still reveals three components (where one or two of the results are A2 and/or P2 and the remainder the result of biological noise), then the readings are combined (superimposed) and the two components with the greatest FWE are selected as A2 and P2, the positions of these A2 and P2 provide the values of A2 and P2.
- the value of A2 is the position of A2 and the value of P2 is the position of P2 as determined via one of the sensors. If at least one of the SI from first or second sensor is greater than 10 ms, all components (A2 and P2) within 10 ms are merged. If only one component results, then the value of both A2 and P2 is the position of this one component and resulting SI is equal to zero. If two components result, then the value of A2 is the position of the first component and the value of P2 the position of the second component.
- SI Splitting Interval
- the values of A2 and P2 are the positions of the two components with the greatest FWE. If four components result, then the values of A2 and P2 are the positions of A2 and P2 from the sensor where the amplitude of components FWE is greater than that of the other sensor. A similar approach is used in the case of multiple sensors.
- the SI for each sub-channel, including combined channels is also calculated.
- the A2 and P2 components in the LF, MF, and HF sub-channels have small variations in positioning because of different frequency content.
- heuristic rules are used to correct those deviations and produce A2 and P2 single values from the combination of A2 and P2 from all sub-channels (LF, MF, HF) as well as any combined values which may have been generated.
- An illustrative example of the heuristic rules applied at block 116 is as follows.
- the SI of the MF channel (1/1.4)*the SI of the MF channel.
- the values of A2, P2 and SI for the current beat are stored at blocks 124 , 126 and 128 .
- values of A2, P2 and SI calculated for beats during the previous minute are retained.
- consistency of solution and signal-to-noise ratio (SNR) for each sub-channel is estimated and stored in separate lists. In this regard, for each sub-range the SNR is estimated. Consistency indicates the percentage of beats not rejected due to high noise.
- the S2 sound is first detected as well as the precise position of the start and end of S2.
- the signal component (S) is calculated as the energy between the start and end of S2, divided by the duration of S2 (in msec).
- the noise component (N) is calculated as the energy within 50 msec segment before the start of S2 added to the energy within 50 msec segment after the end of S2 divided by 100 msec.
- a series of values of A2, P2 and SI are ready for statistical validation.
- the distributions of A2 and P2 are estimated and a threshold location in time from the start of S2 value T calculated using a Bayesian criterion. Typically between 50-200 beats are present during a one minute sampling interval. Histograms are used in order to provide an estimation of the distributions.
- the distribution law of SI is used for additional control of the T value in the case of multi-peak distribution of A2 or P2.
- any values of A2 which are located at a time greater than T from the start of S2 and values of P2 located at a time of less than time T from the Start of S2 are discarded from the stored values.
- the SI values are then recalculated at block 132 using only those A2 and P2 values which still have pairs.
- SI′ is compared with the peak value of SI calculated at block 138 . If the difference between SI and SI′ is less than 1% of the average beat duration, the mean value of SI and SI′ is produced as the final output value for SI. If the difference between SI and SI′ is greater than 1% of the average beat duration, the values of SI, SI′ having a higher consistency value, as previously calculated at blocks 144 , 146 provides the final output value.
- the process channel block 108 can be based on a variety of methods including a Chirplet method, NLEO method, or any other suitable method capable of extracting and discriminating A2 and P2 components from second heart sound S2.
- the NLEO method is described and comprises the following processing steps. Referring to block 108 2 , the Signal to Noise Ratio (SNR) is determined at block 148 .
- SNR Signal to Noise Ratio
- the NLEO method is described in “Adaptive Segmentation of Electroencephalographic Data Using a Nonlinear Energy Operator” by Agarwal, et al., Proceedings IEEE ISCAS '99, Orlando, Fla., 1999, incorporated by reference herein.
- NLEO is a manipulation of digital signal described in the general case by:
- FWE Frequency Weighted Energy
- AWGN additive white Gaussian noise
- NLEO output will enhance FWE of each of these components while suppressing AWGN interference and provide a constant baseline for sinusoidal interference.
- the highest peak (maximum of NLEO output for given beat signal) is determined and those peaks having values within 0.05 of highest peak value are retained. In this regard, 0.05 provides good results, although other values may also provide adequate results. If more than two peaks remain, the A2 and P2 candidates are identified at block 158 . If only one peak is detected, then this is passed to the output and determined as A2 or P2 according to the procedure described hereinabove at paragraph 18 .
- the values of A2 and P2 are validated using list of heuristic rules.
- An illustrative example of such rules are if the time interval between A2 and P2 on NLEO is greater than 100 msec the component with lower FWE is considered invalid and if the time interval between A2 and P2 on NLEO is less than 10 msec, the component having a lower FWE is considered invalid.
Abstract
A pulmonary artery pressure estimator attaches a plurality of acoustic sensors to a patient so as to measure a second heart sound. The sensors are arranged so that an A2 component of the second heart sound is maximized from at least one of the sensors and a P2 component is maximized from at least another one of the sensors. Electrodes are also attached to the patient so as to measure a cardiac interval. A splitting interval is derived from the A2 and P2 components, which is normalized by the cardiac interval. The normalized splitting interval provides an estimation of the pulmonary artery pressure (PAP).
Description
- The present application is a continuation of U.S. patent application Ser. No. 11/578,462 titled Non-Invasive Measurement of Second Heart Sound Components, issuing Mar. 22, 2011 as U.S. Pat. No. 7,909,772, which is the national stage of International Application No. PCT/CA2005/000568 filed Apr. 15, 2005; which claims priority benefit of U.S. Provisional Patent Application No. 60/562,538 titled PAP Estimator, filed Apr. 16, 2004; all the above-referenced provisional, non-provisional and international applications are hereby incorporated by reference herein.
- The highly publicized problem of cardio-vascular diseases, an increased population living excess of eighty and the predominance of the heart disease as a leading cause of death have increased the importance of the clinical practitioner's ability to recognize abnormal heart conditions. Traditionally, non-invasive heart diagnostics is based upon auscultation and a physician's ability to use a stethoscope to recognize specific patterns and phenomena. Through advances in technology, many of these abilities have been automated. For some of these auscultation methods, however, a stable automated procedure has yet to be found.
- Pulmonary artery hypertension is caused by several heart or pulmonary diseases including dysfunction of prosthetic or native heart valves, left ventricular dysfunction, congenital abnormalities of the heart and great vessels, chronic obstructive pulmonary disease, and adult respiratory distress syndrome. Pulmonary artery hypertension is a serious cardiovascular dysfunction that is difficult to assess non-invasively. In patients requiring continuous monitoring or with those suspected of having pulmonary artery hypertension, the pulmonary artery pressure (PAP) is usually measured using a pulmonary arterial catheter. This is an invasive surgical procedure that is associated with significant morbidity and modality. A pulmonary arterial catheter can be left in place for a few days to allow continuous monitoring of PAP of patients in the critical care unit. However, due to the potential risk to patients, catheterization is not recommended for repeated measurements. Nonetheless, regular evaluation of the PAP is very important to identify pulmonary hypertension and subsequently to follow the evolution of the disease and to assess the efficacy of treatment. Consequently, the development of non-invasive methods that allow frequent and accurate measurement of PAP are particularly advantageous.
- Doppler echocardiography is one non-invasive method that can be used to estimate the systolic PAP. If tricuspid regurgitation is detected, it is possible to estimate the systolic pressure gradient across the tricuspid valve using continuous-wave Doppler. The right ventricular systolic pressure can be calculated by sliding the systolic tricuspid valve gradient to the estimated right atrial pressure. The right ventricular systolic pressure can be considered equivalent to the systolic PAP when the systolic pressure gradient across the pulmonary valve is negligible. This noninvasive method can provide a high degree of correlation (0.89<r<0.97) and a standard error estimate (SEE) varying from 7 to 12 mmHg with pulmonary artery catheterization (for systolic PAP range: 20-180 mmHg). However, the estimation of PAP by Doppler echocardiography has several important limitations. First, PAP cannot be estimated by Doppler in approximately 50% of patients with normal PAP, 10 to 20% of patients with elevated PAP and 34 to 76% of patients with chronic obstructive pulmonary disease. This is due to the absence of tricuspid regurgitation, a weak Doppler signal or a poor signal-to-noise ratio. To improve the feasibility of the Doppler echocardiography in some of these patients, it is necessary to use contrast agent enhancement. Second, Doppler echocardiography tends to overestimate PAP in patients with normal PAP and significantly underestimate the PAP in patients with severe pulmonary arterial hypertension.
- A PAP estimation method is based on the spectral properties of the P2 component of the second heart sound. The basic principle supporting this approach is based on Laplace's Law and assumes that the tension of the pulmonary wall is proportional to the corresponding intra-arterial blood pressure. Similar to a stretched drumhead, it is expected that the resonant frequency of the blood column in the pulmonary artery is proportional to the tension in the arterial wall and thus to the arterial pressure. Spectral methods have shown a high correlation between spectral features of P2 and the systolic PAP measured by PA catheterization. The two features were the dominant frequency and the quality factor of the spectrum of P2. In patients with prosthetic heart valves it has been demonstrated that systolic PAP estimated by Doppler echocardiography can be predicted from the spectral features extracted from P2.
- For diagnostic of cardiac events, one of the most interesting sounds is the second heart sound. This sound comprises two components which are generally of interest: the aortic component and the pulmonary component. Detection and recognition of those components provides the possibility of measuring the systole and diastole duration for both the left- and right heart. These values are very important for many applications such as detection of pulmonary artery hypertension, dysfunction of heart valves, left and right ventricular dysfunction, etc.
- As described hereinabove, the second heart sound and the components A2 and P2 thereof have significant clinical value. However, these components are very often masked by noises and other acoustic components of both the heart sounds and other parts of human body. As result, typically only specially trained and experienced clinicians can distinguish the A2 and P2 components. As a result, an automated computer-based procedure for A2 and P2 components would be desirable in clinical practice.
- Cardiac catheterization and echocardiography, which have provided an accurate diagnosis of both right- and left heart abnormalities, have added a new dimension to usefulness of the phonocardiogram in assessing the presence and severity of cardiovascular abnormalities. Although cardiac catheterization generally provides the decisive evidence of the presence and severity of cardiac abnormalities, the external sound recordings correlate sufficiently well with the internal findings for them to serve, in many instances, as diagnostic tool per se. In this regard, phonocardiography often provides information complementary to that obtained by echocardiography. With this enhanced diagnostic accuracy, simpler and less painful external techniques can be used to determine when a patient needs more extensive cardiac treatment. Even in those cases where cardiac catheterization is deemed necessary, the knowledge gained beforehand through phonocardiography and other non-invasive studies can lead to much more efficient and fruitful invasive study.
- An advantageous approach for estimating PAP, described herein, uses advanced signal processing techniques to determine a normalized splitting interval (NSI), which is normalized time interval between the two components of the second heart sound (S2), i.e. the aortic (A2) and pulmonary (P2) components. The splitting interval is normalized by a cardiac interval (CI) derived from an ECG. In an embodiment, the cardiac interval is derived from an average of intervals between a predetermined number of consecutive QRS waves of the ECG.
- A PAP estimator determines a location of pulmonary and aortic components of second heart sounds of a patient over an interval. The method comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, identifying at least one second heart sound in the interval using the electronic representation, for each identified second heart sound calculating a frequency weighted energy (FWE), normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component, and generating an estimated value for a location of the aortic component and the pulmonary component from the candidate values.
- In an embodiment of this method, peaks having an amplitude of a predetermined value between 90% and 100% of the amplitude of the maximum peak are retained. Peaks having an amplitude less than a predetermined value between 90% and 100% of the amplitude of the maximum peak are discarded. Similarly, in an embodiment of this method, peaks are retained which have an amplitude lower than the amplitude of the maximum peak by a value between 0 and 10% of the amplitude of the maximum peak.
- There is also provided a method for estimating a location of pulmonary and aortic components of second heart sounds of a patient over an interval. The method comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, dividing the electronic representation into a plurality of sub-channels, for each of the sub-channel representations, identifying at least one second heart sound in the interval using the electronic representation and extracting an estimated location of a sub-channel aortic component and a sub-channel pulmonary component from the at least one second heart sound, combining the estimated sub-channel aortic component locations to form the estimated aortic component location and the estimated sub-channel pulmonary component locations to form the estimated pulmonary component location.
- Additionally, there is provided a method for estimating a location of pulmonary and aortic components of second heart sounds a patient over an interval. The method comprises the steps of positioning a first transducer at a first position on the patient, the first transducer producing a first electronic representation of heart sounds of the patient over the interval, positioning a second transducer at a second position on the patient, the second transducer producing a second electronic representation of heart sounds of the patient over the interval, for the first electronic representation identifying at least one second heart sound in the interval, for each identified second heart sound calculating a FWE, normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component, and generating a first estimated value for a location of an aortic component and a pulmonary component from the candidate values and for the second electronic representation identifying at least one second heart sound in the interval, for each identified second heart sound calculating a FWE, normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component and generating second estimated values for a location of the aortic component and the pulmonary component from the candidate values and combining the first and second estimated aortic location values and the first and second estimated pulmonary location values wherein the estimated location of the aortic components is the combined first and second estimated aortic location values and the estimated location of the pulmonary components is the combined first and second estimated pulmonary location values.
- Furthermore, there is provided a method for estimating pulmonary artery pressure of a patient over an interval. The method comprises the steps of producing an electronic representation of heart sounds of the patient over the interval, identifying at least one second heart sound in the interval using the electronic representation, for each identified second heart sound calculating a FWE, normalizing the FWE, identifying peaks in the FWE, determining a maximum peak from the identified peaks and retaining the maximum peak and peaks having an amplitude within a predetermined amount of an amplitude of the maximum peak, wherein if two or more peaks are retained, two largest peaks are selected, a first peak as a candidate value for the aortic component and a second peak as a candidate value for the pulmonary component, wherein the first peak is prior to the second peak and wherein if only a single peak is retained, the single peak is selected as a candidate value for the aortic component and generating an estimated value for a location of an aortic component and a location of pulmonary component from the candidate values, determining a splitting interval as a time between the aortic component location and the pulmonary component location, normalizing the splitting interval, and estimating the systolic pulmonary artery pressure using a predetermined function which describes a relationship between the normalized splitting interval and the systolic and diastolic pulmonary artery pressures. Also, there is provided an apparatus implementing any of the above methods.
-
FIG. 1 is a general illustration of a pulmonary artery pressure (PAP) estimator embodiment; -
FIG. 2 are graphs of typical signals detected by a PAP estimator embodiment; -
FIG. 3 is a block diagram of a PAP estimator based upon a normalized splitting interval (SI); and -
FIGS. 4A-B are flow charts of the A2, P2 and SI detection embodiments. -
FIG. 1 generally illustrates a pulmonary artery pressure (PAP)estimator embodiment 10 having two identical biological sound (acoustic)sensors 12, for example those described in U.S. Pat. No. 6,661,161, incorporated by reference herein, are provided for, although in a given application a single sensor or more than two sensors may be preferable. In the case of a multiple sensor schema, sensors are placed at different locations on thepatient 14, where there is expected to be a maximal intensity of the aortic component of the second heart sound A2 or the pulmonary component of the second heart sound P2 or both A2 and P2 signals. In the illustrated example onesensor 121 is positioned at the apex of heart, where the A2 component of the S2 sound is likely at its maximal in intensity and P2 component is minimal. Asecond sensor 122 is placed to maximize the P2 component intensity (between the 3rd and 4th left intercostal space). The best sensor locations are obtained by experimenting with different positions while observing S2 sound signals, so as to achieve the maximal signal intensity. - The
sensors 12 are attached via appropriate leads as in 16 to adata acquisition system 18 comprised of an analog todigital converter 20 andpersonal computer 22. Data collected by thesensors 12 is digitized by the analog todigital converter 20, illustratively using a sampling rate of 2 kHz with 12 bits of resolution. Additionally, electrocardiogram (ECG) signals are also collected via a series ofelectrodes 24, leads 26 and a second analog todigital converter 28. Similar to the acoustic data collected by thebiological sound sensors 12, data collected by theECG electrodes 24 is digitized by the analog todigital converter 28, illustratively using a sampling rate of 2 kHz with 12 bits of resolution. As will be seen below, the electrocardiogram is used as the reference signal to frame the second heart sound (S2). -
FIG. 2 illustrates typical signals detected by a PAP estimator embodiment, including an ECG reading displayed along side readings from first and second biological sound (acoustic) sensors. The ECG is used to provide the reference signal to frame the second heart sound. The ECG is also to determine a normalizing cardiac interval for the calculated splitting interval (SI). The beat signal in the description below means the part of acoustic signal between two consecutive QRS complexes on the ECG. Depending on the selected approach, the ‘beat signal” can be defined as the Q-Q’ (distance between two Q markers) or as the R-R′ (distance between two R markers). In the following description Q-Q′ provides the beat signal. For each beat signal the first heart signal (S1) is detected and removed. The remaining sounds, including the second heart sounds and possibly murmurs and the like, are then used as input. -
FIG. 3 illustrates a pulmonary artery pressure (PAP)estimator 300 having acoustic sensor(s) 12 andECG sensors 24 inputs. The acoustic sensor(s) 12 are used to measure second heart sounds 400 (FIGS. 4A-B ) so that the data acquisition system 18 (FIG. 1 ) derives a splitting interval (SI) 310 output. TheECG sensors 24 are used by the data acquisition system 18 (FIG. 1 ) to frame the second heart sounds so as to deriveS2 measurements 400 and to derive a cardiac interval (CI) 320. In an embodiment,CI 320 is based uponsuccessive QRS intervals 300 of theECG sensors 24 input. The data acquisition system 18 (FIG. 1 ) utilizes CI to normalize SI 330 (NSI) so as to generate aPAP estimate 340 output. -
FIGS. 4A-B illustrate aortic component (A2), pulmonary component (P2) and splitting interval (SI) detection embodiments. The illustrative method supports input signals from the single or multiple sensor(s) 12, each of them comprised of signals of heart sounds in the frequency range 30-200 Hz, although this range could be wider without any changes in the approach. If that range is narrower, however, the method should be adapted to those limitations. - As shown in
FIG. 4A , sounds related to heart beats are collected at 100 via a sensor(s) 12 and illustratively divided into threesub channels - Each sub-channel is relayed to a “Process Channel” block as in 1081, 1082, and 1083, (these will be described separately below). The process channel block can be based on a variety of methods including a Chirplet method, Nonlinear Energy Operator (NLEO) method, or any other suitable method capable of extracting and discriminating A2 and P2 components from second heart sound S2. The illustrated embodiment applies the NLEO method.
- The output values of A2 and P2 from the process channel blocks as in 1081, 1082, and 1083 are analyzed. If both components A2, P2 are clearly detectable in at least one of the sub channels, these are the values for A2, P2. If both components are not clearly detectable then the outputs of the process channel blocks as in 1081, 1082, and 1083 are compared sub-channel by sub-channel with the output of the process channel blocks for other sensors (not shown) of the same sub channels at
blocks - Illustratively, the comparison is carried out on each frequency band according to the following set of rules, although it should be understood that this is an example and not intended to be limiting. If the output of 108 for both sensors reveals A2 and P2 components and the positions of A2 and P2 in each sensor output are the same, then these positions provide the values of A2 and P2. If one of the outputs of 108 for both sensors reveals A2 and P2 components, but the other does not, then the positions of these A2 and P2 provide the values of A2 and P2. If the output of 108 for both sensors reveals only one A2 or one P2 component then, as it is unknown whether the component is A2 or P2, then the value of A2 is the position of the first component and the value of P2 the position of the second component. If the output of 108 for one of the sensors reveals both A2 and P2 components while the output of 108 for the other sensor reveals only one (A2 or P2) component, then the readings for both sensors are combined (superimposed). If the result reveals only two components (A2 and P2) then the positions of these A2 and P2 provide the values of A2 and P2. If the result still reveals three components (where one or two of the results are A2 and/or P2 and the remainder the result of biological noise), then the readings are combined (superimposed) and the two components with the greatest FWE are selected as A2 and P2, the positions of these A2 and P2 provide the values of A2 and P2.
- If the output of 108 for both sensors reveals A2 and P2 components but the positions of A2 and P2 are different, then, if the Splitting Interval (SI) of both sensors is less than 10 ms then the value of A2 is the position of A2 and the value of P2 is the position of P2 as determined via one of the sensors. If at least one of the SI from first or second sensor is greater than 10 ms, all components (A2 and P2) within 10 ms are merged. If only one component results, then the value of both A2 and P2 is the position of this one component and resulting SI is equal to zero. If two components result, then the value of A2 is the position of the first component and the value of P2 the position of the second component. If three components result, then the values of A2 and P2 are the positions of the two components with the greatest FWE. If four components result, then the values of A2 and P2 are the positions of A2 and P2 from the sensor where the amplitude of components FWE is greater than that of the other sensor. A similar approach is used in the case of multiple sensors.
- Also shown in
FIG. 4A , the SI for each sub-channel, including combined channels, is also calculated. The A2 and P2 components in the LF, MF, and HF sub-channels have small variations in positioning because of different frequency content. As a result, atblock 116, heuristic rules are used to correct those deviations and produce A2 and P2 single values from the combination of A2 and P2 from all sub-channels (LF, MF, HF) as well as any combined values which may have been generated. An illustrative example of the heuristic rules applied atblock 116 is as follows. If no values for both A2 and P2 are available in the MF and HF sub-channels and the SI of the LF channel>120 msec, then discard the SI of the LF channel. If values for both A2 and P2 are available in the LF and HF sub-channels and the SI of the LF channel>1.4*SI of the HF channel, then discard the SI of the LF channel. If values for both A2 and P2 are available in the LF and MF sub-channels, and the SI of the LF channel>1.4*the SI of the MF channel, then the SI of the LF channel=1.4*the SI of the MF channel. If values for both A2 and P2 are available in the MF and HF sub-channels, and the SI of the MF channel<1.4*the SI of the HF channel, then the SI of the HF channel=(1/1.4)*the SI of the MF channel. - As shown in
FIG. 4B , the values of A2, P2 and SI for the current beat are stored atblocks - After all beats within the time averaging interval (in the case at hand illustratively 1 minute) have been processed in the above manner, a series of values of A2, P2 and SI are ready for statistical validation. At a first step of the validation process the distributions of A2 and P2 are estimated and a threshold location in time from the start of S2 value T calculated using a Bayesian criterion. Typically between 50-200 beats are present during a one minute sampling interval. Histograms are used in order to provide an estimation of the distributions. The distribution law of SI is used for additional control of the T value in the case of multi-peak distribution of A2 or P2.
- At
block 130, any values of A2 which are located at a time greater than T from the start of S2 and values of P2 located at a time of less than time T from the Start of S2 are discarded from the stored values. The SI values are then recalculated atblock 132 using only those A2 and P2 values which still have pairs. - At
blocks block 140 the value SI′=P2−A2 is calculated. - At
block 142, SI′ is compared with the peak value of SI calculated atblock 138. If the difference between SI and SI′ is less than 1% of the average beat duration, the mean value of SI and SI′ is produced as the final output value for SI. If the difference between SI and SI′ is greater than 1% of the average beat duration, the values of SI, SI′ having a higher consistency value, as previously calculated atblocks - As shown in
FIG. 4A , as stated above, the process channel block 108 can be based on a variety of methods including a Chirplet method, NLEO method, or any other suitable method capable of extracting and discriminating A2 and P2 components from second heart sound S2. Illustratively, the NLEO method is described and comprises the following processing steps. Referring to block 108 2, the Signal to Noise Ratio (SNR) is determined atblock 148. The NLEO method is described in “Adaptive Segmentation of Electroencephalographic Data Using a Nonlinear Energy Operator” by Agarwal, et al., Proceedings IEEE ISCAS '99, Orlando, Fla., 1999, incorporated by reference herein. - At
decision block 150, if the SNR is below a predetermined value (illustratively 1.5), the current beat in the channel being processed is discarded and no further processing steps carried out. Alternatively, if the SNR is above a predetermined value the NLEO function is calculated atblock 154 using the current beat's signal. In this regard, the NLEO or any other individual implementation of FWE or any other individual implementation of the general family of Autocorrelators may be used. NLEO is a manipulation of digital signal described in the general case by: -
ψ[n]=x(n−l)·x(n−m)−x(n−p)·x(n−q) for l+m=p+q (1) - One of NLEO's special properties is the ability to compactly describe the notion of a Frequency Weighted Energy (FWE), which is different from the mean-square energy as it reflects both the amplitude as well as the frequency content of a signal. For the special case where l≠m and p≠q, given an input of additive white Gaussian noise (AWGN) the expected value of NLEO output is zero. Thus it has the ability to suppress noise. If we consider the case of an amplitude modulated short duration sinusoidal burst in the presence of random noise and structured sinusoidal interference (as in the case of the aortic and the pulmonary components of the S2 sound in the midst of noise), it is anticipated that the NLEO output will enhance FWE of each of these components while suppressing AWGN interference and provide a constant baseline for sinusoidal interference. The time-varying nature of amplitude (Gaussian) and chirping of the dominant rhythm will modulate the NLEO output and produce a detectable burst corresponding to each component in contrast to background clutter. It will then be possible to apply detection strategies on the NLEO output with S2 sound input. Illustratively, NLEO with parameters l=2, m=3, p=1, q=4 was applied.
- Once the NLEO function is calculated, at
block 156 the highest peak (maximum of NLEO output for given beat signal) is determined and those peaks having values within 0.05 of highest peak value are retained. In this regard, 0.05 provides good results, although other values may also provide adequate results. If more than two peaks remain, the A2 and P2 candidates are identified atblock 158. If only one peak is detected, then this is passed to the output and determined as A2 or P2 according to the procedure described hereinabove atparagraph 18. - Finally, at
block 160 the values of A2 and P2 are validated using list of heuristic rules. An illustrative example of such rules are if the time interval between A2 and P2 on NLEO is greater than 100 msec the component with lower FWE is considered invalid and if the time interval between A2 and P2 on NLEO is less than 10 msec, the component having a lower FWE is considered invalid. - A non-invasive PAP estimator has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in art will appreciate many variations and modifications.
Claims (2)
1. A pulmonary artery pressure estimator comprising:
a first biological sound sensor located on a person proximate the apex of the heart so that an A2 component of a second heart sound is maximal in intensity and a P2 component of the second heart sound is minimal in intensity;
a second biological sound sensor located on the person proximately between the third and fourth left intercostal space so that the P2 component is maximal in intensity;
a plurality of electrodes located on the person so as to generate ECG signals;
a data acquisition system in communications with the sound sensors and electrodes so as to derive the second heart sounds components from the sound sensors and an ECG from the electrode ECG signals;
the data acquisition system derives a splitting interval (SI=P2−A2) from the sound sensors;
the data acquisition system derives a cardiac interval (CI) from the electrodes; and
the data acquisition system estimates a pulmonary artery pressure from the splitting interval normalized by the cardiac interval.
2. A pulmonary artery pressure estimating method comprising:
attaching a first acoustic sensor and a second acoustic sensor to a person so as to measure a second heart sound;
locating the first acoustic sensor on the person so as to maximize an A2 component of the second heart sound and minimize a P2 component of the second heart sound;
locating the second acoustic sensor on the person so as to maximize the P2 component;
attaching electrodes to the person so as to measure an ECG;
deriving a splitting interval from the first and second acoustic sensors;
deriving a cardiac interval from the electrodes; and
estimating a pulmonary artery pressure from the splitting interval normalized by the cardiac interval.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/053,202 US20120071767A1 (en) | 2004-04-16 | 2011-03-21 | Pulmonary artery pressure estimator |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56253804P | 2004-04-16 | 2004-04-16 | |
CA002464634A CA2464634A1 (en) | 2004-04-16 | 2004-04-16 | Pap estimator |
PCT/CA2005/000568 WO2005099562A1 (en) | 2004-04-16 | 2005-04-15 | Non-invasive measurement of second heart sound components |
US57846207A | 2007-08-13 | 2007-08-13 | |
US13/053,202 US20120071767A1 (en) | 2004-04-16 | 2011-03-21 | Pulmonary artery pressure estimator |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/578,462 Continuation US7909772B2 (en) | 2004-04-16 | 2005-04-15 | Non-invasive measurement of second heart sound components |
PCT/CA2005/000568 Continuation WO2005099562A1 (en) | 2004-04-16 | 2005-04-15 | Non-invasive measurement of second heart sound components |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120071767A1 true US20120071767A1 (en) | 2012-03-22 |
Family
ID=35276856
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/578,462 Active 2027-08-23 US7909772B2 (en) | 2004-04-16 | 2005-04-15 | Non-invasive measurement of second heart sound components |
US13/053,202 Abandoned US20120071767A1 (en) | 2004-04-16 | 2011-03-21 | Pulmonary artery pressure estimator |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/578,462 Active 2027-08-23 US7909772B2 (en) | 2004-04-16 | 2005-04-15 | Non-invasive measurement of second heart sound components |
Country Status (5)
Country | Link |
---|---|
US (2) | US7909772B2 (en) |
EP (1) | EP1744666A1 (en) |
JP (1) | JP2007532207A (en) |
CA (2) | CA2464634A1 (en) |
WO (1) | WO2005099562A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184315A1 (en) * | 2012-06-05 | 2013-12-12 | 3M Innovative Properties Company | Enhanced auscultatory sensor and analysis for patient diagnosis |
Families Citing this family (283)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9702434A (en) | 1991-03-07 | 1998-05-31 | Masimo Corp | Signal processing apparatus. |
US5638818A (en) | 1991-03-21 | 1997-06-17 | Masimo Corporation | Low noise optical probe |
US8019400B2 (en) | 1994-10-07 | 2011-09-13 | Masimo Corporation | Signal processing apparatus |
EP1905352B1 (en) | 1994-10-07 | 2014-07-16 | Masimo Corporation | Signal processing method |
US5758644A (en) | 1995-06-07 | 1998-06-02 | Masimo Corporation | Manual and automatic probe calibration |
US6002952A (en) | 1997-04-14 | 1999-12-14 | Masimo Corporation | Signal processing apparatus and method |
US6229856B1 (en) | 1997-04-14 | 2001-05-08 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
WO1999062399A1 (en) | 1998-06-03 | 1999-12-09 | Masimo Corporation | Stereo pulse oximeter |
US6721585B1 (en) | 1998-10-15 | 2004-04-13 | Sensidyne, Inc. | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
US7245953B1 (en) | 1999-04-12 | 2007-07-17 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US6463311B1 (en) | 1998-12-30 | 2002-10-08 | Masimo Corporation | Plethysmograph pulse recognition processor |
US6684090B2 (en) | 1999-01-07 | 2004-01-27 | Masimo Corporation | Pulse oximetry data confidence indicator |
US6360114B1 (en) | 1999-03-25 | 2002-03-19 | Masimo Corporation | Pulse oximeter probe-off detector |
US6515273B2 (en) * | 1999-08-26 | 2003-02-04 | Masimo Corporation | System for indicating the expiration of the useful operating life of a pulse oximetry sensor |
US6377829B1 (en) | 1999-12-09 | 2002-04-23 | Masimo Corporation | Resposable pulse oximetry sensor |
DE60139128D1 (en) | 2000-08-18 | 2009-08-13 | Masimo Corp | PULSE OXIMETER WITH TWO OPERATING MODES |
US6850787B2 (en) | 2001-06-29 | 2005-02-01 | Masimo Laboratories, Inc. | Signal component processor |
US6697658B2 (en) | 2001-07-02 | 2004-02-24 | Masimo Corporation | Low power pulse oximeter |
US7355512B1 (en) | 2002-01-24 | 2008-04-08 | Masimo Corporation | Parallel alarm processor |
US6850788B2 (en) | 2002-03-25 | 2005-02-01 | Masimo Corporation | Physiological measurement communications adapter |
US6970792B1 (en) | 2002-12-04 | 2005-11-29 | Masimo Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US7919713B2 (en) * | 2007-04-16 | 2011-04-05 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US6920345B2 (en) | 2003-01-24 | 2005-07-19 | Masimo Corporation | Optical sensor including disposable and reusable elements |
AU2004262509A1 (en) | 2003-04-23 | 2005-02-17 | Medscansonics, Inc. | Apparatus and method for non-invasive diagnosing of coronary artery disease |
US7003338B2 (en) | 2003-07-08 | 2006-02-21 | Masimo Corporation | Method and apparatus for reducing coupling between signals |
US7500950B2 (en) | 2003-07-25 | 2009-03-10 | Masimo Corporation | Multipurpose sensor port |
US7483729B2 (en) | 2003-11-05 | 2009-01-27 | Masimo Corporation | Pulse oximeter access apparatus and method |
US7438683B2 (en) | 2004-03-04 | 2008-10-21 | Masimo Corporation | Application identification sensor |
EP1722676B1 (en) | 2004-03-08 | 2012-12-19 | Masimo Corporation | Physiological parameter system |
CA2464029A1 (en) * | 2004-04-08 | 2005-10-08 | Valery Telfort | Non-invasive ventilation monitor |
US9341565B2 (en) * | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multiple-wavelength physiological monitor |
US7343186B2 (en) | 2004-07-07 | 2008-03-11 | Masimo Laboratories, Inc. | Multi-wavelength physiological monitor |
US7937128B2 (en) | 2004-07-09 | 2011-05-03 | Masimo Corporation | Cyanotic infant sensor |
US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US7761127B2 (en) | 2005-03-01 | 2010-07-20 | Masimo Laboratories, Inc. | Multiple wavelength sensor substrate |
CA2604653A1 (en) | 2005-04-13 | 2006-10-19 | Glucolight Corporation | Method for data reduction and calibration of an oct-based blood glucose monitor |
US7962188B2 (en) | 2005-10-14 | 2011-06-14 | Masimo Corporation | Robust alarm system |
WO2007064984A2 (en) | 2005-11-29 | 2007-06-07 | Masimo Corporation | Optical sensor including disposable and reusable elements |
JP4904488B2 (en) * | 2006-01-17 | 2012-03-28 | 国立大学法人 長崎大学 | Lung sound diagnostic device |
US8182443B1 (en) | 2006-01-17 | 2012-05-22 | Masimo Corporation | Drug administration controller |
US8219172B2 (en) | 2006-03-17 | 2012-07-10 | Glt Acquisition Corp. | System and method for creating a stable optical interface |
US8920343B2 (en) | 2006-03-23 | 2014-12-30 | Michael Edward Sabatino | Apparatus for acquiring and processing of physiological auditory signals |
US9176141B2 (en) | 2006-05-15 | 2015-11-03 | Cercacor Laboratories, Inc. | Physiological monitor calibration system |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US8998809B2 (en) * | 2006-05-15 | 2015-04-07 | Cercacor Laboratories, Inc. | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
US8028701B2 (en) | 2006-05-31 | 2011-10-04 | Masimo Corporation | Respiratory monitoring |
US10188348B2 (en) | 2006-06-05 | 2019-01-29 | Masimo Corporation | Parameter upgrade system |
US8457707B2 (en) | 2006-09-20 | 2013-06-04 | Masimo Corporation | Congenital heart disease monitor |
US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
US9161696B2 (en) * | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
US9861305B1 (en) | 2006-10-12 | 2018-01-09 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US7880626B2 (en) | 2006-10-12 | 2011-02-01 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US8265723B1 (en) | 2006-10-12 | 2012-09-11 | Cercacor Laboratories, Inc. | Oximeter probe off indicator defining probe off space |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
US8280473B2 (en) | 2006-10-12 | 2012-10-02 | Masino Corporation, Inc. | Perfusion index smoother |
US9192329B2 (en) | 2006-10-12 | 2015-11-24 | Masimo Corporation | Variable mode pulse indicator |
US8600467B2 (en) | 2006-11-29 | 2013-12-03 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
EP2096994B1 (en) | 2006-12-09 | 2018-10-03 | Masimo Corporation | Plethysmograph variability determination |
US8852094B2 (en) | 2006-12-22 | 2014-10-07 | Masimo Corporation | Physiological parameter system |
US8652060B2 (en) | 2007-01-20 | 2014-02-18 | Masimo Corporation | Perfusion trend indicator |
US20090093687A1 (en) * | 2007-03-08 | 2009-04-09 | Telfort Valery G | Systems and methods for determining a physiological condition using an acoustic monitor |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US8764671B2 (en) | 2007-06-28 | 2014-07-01 | Masimo Corporation | Disposable active pulse sensor |
US8048040B2 (en) | 2007-09-13 | 2011-11-01 | Masimo Corporation | Fluid titration system |
US8310336B2 (en) | 2008-10-10 | 2012-11-13 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
JP5296793B2 (en) | 2007-10-12 | 2013-09-25 | マシモ コーポレイション | Connector assembly |
US8768423B2 (en) | 2008-03-04 | 2014-07-01 | Glt Acquisition Corp. | Multispot monitoring for use in optical coherence tomography |
CN101959462B (en) * | 2008-03-04 | 2013-05-22 | 皇家飞利浦电子股份有限公司 | Non invasive analysis of body sounds |
WO2009134724A1 (en) | 2008-05-02 | 2009-11-05 | Masimo Corporation | Monitor configuration system |
US9107625B2 (en) | 2008-05-05 | 2015-08-18 | Masimo Corporation | Pulse oximetry system with electrical decoupling circuitry |
US20100004518A1 (en) | 2008-07-03 | 2010-01-07 | Masimo Laboratories, Inc. | Heat sink for noninvasive medical sensor |
US8203438B2 (en) | 2008-07-29 | 2012-06-19 | Masimo Corporation | Alarm suspend system |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
US8911377B2 (en) * | 2008-09-15 | 2014-12-16 | Masimo Corporation | Patient monitor including multi-parameter graphical display |
SE532941C2 (en) | 2008-09-15 | 2010-05-18 | Phasein Ab | Gas sampling line for breathing gases |
US8401602B2 (en) | 2008-10-13 | 2013-03-19 | Masimo Corporation | Secondary-emitter sensor position indicator |
US8346330B2 (en) | 2008-10-13 | 2013-01-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US8771204B2 (en) | 2008-12-30 | 2014-07-08 | Masimo Corporation | Acoustic sensor assembly |
US8588880B2 (en) * | 2009-02-16 | 2013-11-19 | Masimo Corporation | Ear sensor |
US10007758B2 (en) | 2009-03-04 | 2018-06-26 | Masimo Corporation | Medical monitoring system |
US9218454B2 (en) | 2009-03-04 | 2015-12-22 | Masimo Corporation | Medical monitoring system |
US10032002B2 (en) | 2009-03-04 | 2018-07-24 | Masimo Corporation | Medical monitoring system |
US9323894B2 (en) | 2011-08-19 | 2016-04-26 | Masimo Corporation | Health care sanitation monitoring system |
US8388353B2 (en) | 2009-03-11 | 2013-03-05 | Cercacor Laboratories, Inc. | Magnetic connector |
US20100234718A1 (en) * | 2009-03-12 | 2010-09-16 | Anand Sampath | Open architecture medical communication system |
WO2010135373A1 (en) | 2009-05-19 | 2010-11-25 | Masimo Corporation | Disposable components for reusable physiological sensor |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US20110040197A1 (en) * | 2009-07-20 | 2011-02-17 | Masimo Corporation | Wireless patient monitoring system |
US20110208015A1 (en) * | 2009-07-20 | 2011-08-25 | Masimo Corporation | Wireless patient monitoring system |
US8471713B2 (en) | 2009-07-24 | 2013-06-25 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US20110028806A1 (en) * | 2009-07-29 | 2011-02-03 | Sean Merritt | Reflectance calibration of fluorescence-based glucose measurements |
US20110028809A1 (en) * | 2009-07-29 | 2011-02-03 | Masimo Corporation | Patient monitor ambient display device |
US8473020B2 (en) | 2009-07-29 | 2013-06-25 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US20110087081A1 (en) * | 2009-08-03 | 2011-04-14 | Kiani Massi Joe E | Personalized physiological monitor |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
US20110172498A1 (en) * | 2009-09-14 | 2011-07-14 | Olsen Gregory A | Spot check monitor credit system |
US9579039B2 (en) | 2011-01-10 | 2017-02-28 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US20110137297A1 (en) | 2009-09-17 | 2011-06-09 | Kiani Massi Joe E | Pharmacological management system |
WO2011035070A1 (en) | 2009-09-17 | 2011-03-24 | Masimo Laboratories, Inc. | Improving analyte monitoring using one or more accelerometers |
US8571618B1 (en) | 2009-09-28 | 2013-10-29 | Cercacor Laboratories, Inc. | Adaptive calibration system for spectrophotometric measurements |
US20110082711A1 (en) * | 2009-10-06 | 2011-04-07 | Masimo Laboratories, Inc. | Personal digital assistant or organizer for monitoring glucose levels |
WO2011047211A1 (en) | 2009-10-15 | 2011-04-21 | Masimo Corporation | Pulse oximetry system with low noise cable hub |
EP2488106B1 (en) | 2009-10-15 | 2020-07-08 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US9066680B1 (en) | 2009-10-15 | 2015-06-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
WO2011047216A2 (en) | 2009-10-15 | 2011-04-21 | Masimo Corporation | Physiological acoustic monitoring system |
US10463340B2 (en) | 2009-10-15 | 2019-11-05 | Masimo Corporation | Acoustic respiratory monitoring systems and methods |
US8790268B2 (en) | 2009-10-15 | 2014-07-29 | Masimo Corporation | Bidirectional physiological information display |
US9848800B1 (en) | 2009-10-16 | 2017-12-26 | Masimo Corporation | Respiratory pause detector |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
DE112010004682T5 (en) | 2009-12-04 | 2013-03-28 | Masimo Corporation | Calibration for multi-level physiological monitors |
US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
DE112011100282T5 (en) * | 2010-01-19 | 2012-11-29 | Masimo Corporation | Wellness assessment system |
DE112011100761T5 (en) | 2010-03-01 | 2013-01-03 | Masimo Corporation | Adaptive alarm system |
WO2011112524A1 (en) | 2010-03-08 | 2011-09-15 | Masimo Corporation | Reprocessing of a physiological sensor |
US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
JP5531715B2 (en) * | 2010-03-30 | 2014-06-25 | コニカミノルタ株式会社 | Biological information measuring apparatus and method |
US9138180B1 (en) | 2010-05-03 | 2015-09-22 | Masimo Corporation | Sensor adapter cable |
US8712494B1 (en) | 2010-05-03 | 2014-04-29 | Masimo Corporation | Reflective non-invasive sensor |
US8666468B1 (en) | 2010-05-06 | 2014-03-04 | Masimo Corporation | Patient monitor for determining microcirculation state |
US9326712B1 (en) | 2010-06-02 | 2016-05-03 | Masimo Corporation | Opticoustic sensor |
JP5488913B2 (en) * | 2010-07-07 | 2014-05-14 | 学校法人福岡大学 | Central blood pressure measurement device, cardiac load measurement device, central blood pressure measurement method, and cardiac load measurement method |
US8740792B1 (en) | 2010-07-12 | 2014-06-03 | Masimo Corporation | Patient monitor capable of accounting for environmental conditions |
US9408542B1 (en) | 2010-07-22 | 2016-08-09 | Masimo Corporation | Non-invasive blood pressure measurement system |
WO2012027613A1 (en) | 2010-08-26 | 2012-03-01 | Masimo Corporation | Blood pressure measurement system |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
JP5710767B2 (en) | 2010-09-28 | 2015-04-30 | マシモ コーポレイション | Depth of consciousness monitor including oximeter |
US8753292B2 (en) * | 2010-10-01 | 2014-06-17 | Angiodynamics, Inc. | Method for locating a catheter tip using audio detection |
US9211095B1 (en) | 2010-10-13 | 2015-12-15 | Masimo Corporation | Physiological measurement logic engine |
US8723677B1 (en) | 2010-10-20 | 2014-05-13 | Masimo Corporation | Patient safety system with automatically adjusting bed |
US20120226117A1 (en) | 2010-12-01 | 2012-09-06 | Lamego Marcelo M | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US8475396B2 (en) | 2011-02-11 | 2013-07-02 | AventuSoft, LLC | Method and system of an acoustic scene analyzer for body sounds |
WO2012109671A1 (en) | 2011-02-13 | 2012-08-16 | Masimo Corporation | Medical characterization system |
US9066666B2 (en) | 2011-02-25 | 2015-06-30 | Cercacor Laboratories, Inc. | Patient monitor for monitoring microcirculation |
US8830449B1 (en) | 2011-04-18 | 2014-09-09 | Cercacor Laboratories, Inc. | Blood analysis system |
US9095316B2 (en) | 2011-04-20 | 2015-08-04 | Masimo Corporation | System for generating alarms based on alarm patterns |
EP2517621A1 (en) | 2011-04-29 | 2012-10-31 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | A radar apparatus for detecting multiple life-signs of a subject, a method and a computer program product |
US9622692B2 (en) | 2011-05-16 | 2017-04-18 | Masimo Corporation | Personal health device |
US9986919B2 (en) | 2011-06-21 | 2018-06-05 | Masimo Corporation | Patient monitoring system |
US9532722B2 (en) | 2011-06-21 | 2017-01-03 | Masimo Corporation | Patient monitoring system |
US9245668B1 (en) | 2011-06-29 | 2016-01-26 | Cercacor Laboratories, Inc. | Low noise cable providing communication between electronic sensor components and patient monitor |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US9192351B1 (en) | 2011-07-22 | 2015-11-24 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US8755872B1 (en) | 2011-07-28 | 2014-06-17 | Masimo Corporation | Patient monitoring system for indicating an abnormal condition |
US9782077B2 (en) | 2011-08-17 | 2017-10-10 | Masimo Corporation | Modulated physiological sensor |
US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
US9808188B1 (en) | 2011-10-13 | 2017-11-07 | Masimo Corporation | Robust fractional saturation determination |
EP3603502B1 (en) | 2011-10-13 | 2023-10-04 | Masimo Corporation | Physiological acoustic monitoring system |
WO2013056160A2 (en) | 2011-10-13 | 2013-04-18 | Masimo Corporation | Medical monitoring hub |
US9778079B1 (en) | 2011-10-27 | 2017-10-03 | Masimo Corporation | Physiological monitor gauge panel |
US9445759B1 (en) | 2011-12-22 | 2016-09-20 | Cercacor Laboratories, Inc. | Blood glucose calibration system |
US9392945B2 (en) | 2012-01-04 | 2016-07-19 | Masimo Corporation | Automated CCHD screening and detection |
US11172890B2 (en) | 2012-01-04 | 2021-11-16 | Masimo Corporation | Automated condition screening and detection |
US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
US9480435B2 (en) | 2012-02-09 | 2016-11-01 | Masimo Corporation | Configurable patient monitoring system |
US10149616B2 (en) | 2012-02-09 | 2018-12-11 | Masimo Corporation | Wireless patient monitoring device |
US8764674B2 (en) | 2012-03-08 | 2014-07-01 | Medtronic, Inc. | Heart sound monitoring of pulmonary hypertension |
US9195385B2 (en) | 2012-03-25 | 2015-11-24 | Masimo Corporation | Physiological monitor touchscreen interface |
JP6490577B2 (en) | 2012-04-17 | 2019-03-27 | マシモ・コーポレイション | How to operate a pulse oximeter device |
WO2013184965A1 (en) | 2012-06-07 | 2013-12-12 | Masimo Corporation | Depth of consciousness monitor |
US9697928B2 (en) | 2012-08-01 | 2017-07-04 | Masimo Corporation | Automated assembly sensor cable |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
US9955937B2 (en) | 2012-09-20 | 2018-05-01 | Masimo Corporation | Acoustic patient sensor coupler |
US9877650B2 (en) | 2012-09-20 | 2018-01-30 | Masimo Corporation | Physiological monitor with mobile computing device connectivity |
US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
US9717458B2 (en) | 2012-10-20 | 2017-08-01 | Masimo Corporation | Magnetic-flap optical sensor |
US9560996B2 (en) | 2012-10-30 | 2017-02-07 | Masimo Corporation | Universal medical system |
US9787568B2 (en) | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9750461B1 (en) | 2013-01-02 | 2017-09-05 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9724025B1 (en) | 2013-01-16 | 2017-08-08 | Masimo Corporation | Active-pulse blood analysis system |
US9750442B2 (en) | 2013-03-09 | 2017-09-05 | Masimo Corporation | Physiological status monitor |
WO2014164139A1 (en) | 2013-03-13 | 2014-10-09 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US10441181B1 (en) | 2013-03-13 | 2019-10-15 | Masimo Corporation | Acoustic pulse and respiration monitoring system |
US9936917B2 (en) | 2013-03-14 | 2018-04-10 | Masimo Laboratories, Inc. | Patient monitor placement indicator |
WO2014158820A1 (en) | 2013-03-14 | 2014-10-02 | Cercacor Laboratories, Inc. | Patient monitor as a minimally invasive glucometer |
US9986952B2 (en) | 2013-03-14 | 2018-06-05 | Masimo Corporation | Heart sound simulator |
US10456038B2 (en) | 2013-03-15 | 2019-10-29 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
US9891079B2 (en) | 2013-07-17 | 2018-02-13 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
WO2015020911A2 (en) | 2013-08-05 | 2015-02-12 | Cercacor Laboratories, Inc. | Blood pressure monitor with valve-chamber assembly |
WO2015038683A2 (en) | 2013-09-12 | 2015-03-19 | Cercacor Laboratories, Inc. | Medical device management system |
US10010276B2 (en) | 2013-10-07 | 2018-07-03 | Masimo Corporation | Regional oximetry user interface |
US11147518B1 (en) | 2013-10-07 | 2021-10-19 | Masimo Corporation | Regional oximetry signal processor |
US10828007B1 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Acoustic sensor with attachment portion |
US10832818B2 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Alarm notification system |
US10279247B2 (en) | 2013-12-13 | 2019-05-07 | Masimo Corporation | Avatar-incentive healthcare therapy |
US11259745B2 (en) | 2014-01-28 | 2022-03-01 | Masimo Corporation | Autonomous drug delivery system |
US10086138B1 (en) | 2014-01-28 | 2018-10-02 | Masimo Corporation | Autonomous drug delivery system |
US10532174B2 (en) | 2014-02-21 | 2020-01-14 | Masimo Corporation | Assistive capnography device |
US9924897B1 (en) | 2014-06-12 | 2018-03-27 | Masimo Corporation | Heated reprocessing of physiological sensors |
US10123729B2 (en) | 2014-06-13 | 2018-11-13 | Nanthealth, Inc. | Alarm fatigue management systems and methods |
US10231670B2 (en) | 2014-06-19 | 2019-03-19 | Masimo Corporation | Proximity sensor in pulse oximeter |
US10111591B2 (en) | 2014-08-26 | 2018-10-30 | Nanthealth, Inc. | Real-time monitoring systems and methods in a healthcare environment |
US10231657B2 (en) | 2014-09-04 | 2019-03-19 | Masimo Corporation | Total hemoglobin screening sensor |
US10383520B2 (en) | 2014-09-18 | 2019-08-20 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
WO2016057553A1 (en) | 2014-10-07 | 2016-04-14 | Masimo Corporation | Modular physiological sensors |
KR102575058B1 (en) | 2015-01-23 | 2023-09-05 | 마시모 스웨덴 에이비 | Nasal/Oral Cannula Systems and Manufacturing |
KR102609605B1 (en) | 2015-02-06 | 2023-12-05 | 마시모 코오퍼레이션 | Fold flex circuit for optical probes |
US10568553B2 (en) | 2015-02-06 | 2020-02-25 | Masimo Corporation | Soft boot pulse oximetry sensor |
USD755392S1 (en) | 2015-02-06 | 2016-05-03 | Masimo Corporation | Pulse oximetry sensor |
MX2017010045A (en) | 2015-02-06 | 2018-04-10 | Masimo Corp | Connector assembly with pogo pins for use with medical sensors. |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
WO2016191307A1 (en) | 2015-05-22 | 2016-12-01 | Cercacor Laboratories, Inc. | Non-invasive optical physiological differential pathlength sensor |
US10448871B2 (en) | 2015-07-02 | 2019-10-22 | Masimo Corporation | Advanced pulse oximetry sensor |
EP3334334A1 (en) | 2015-08-11 | 2018-06-20 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
AU2016315947B2 (en) | 2015-08-31 | 2021-02-18 | Masimo Corporation | Wireless patient monitoring systems and methods |
US11504066B1 (en) | 2015-09-04 | 2022-11-22 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11679579B2 (en) | 2015-12-17 | 2023-06-20 | Masimo Corporation | Varnish-coated release liner |
US10993662B2 (en) | 2016-03-04 | 2021-05-04 | Masimo Corporation | Nose sensor |
US10537285B2 (en) | 2016-03-04 | 2020-01-21 | Masimo Corporation | Nose sensor |
US11191484B2 (en) | 2016-04-29 | 2021-12-07 | Masimo Corporation | Optical sensor tape |
US10608817B2 (en) | 2016-07-06 | 2020-03-31 | Masimo Corporation | Secure and zero knowledge data sharing for cloud applications |
US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
US11020011B2 (en) * | 2016-07-20 | 2021-06-01 | Cardiac Pacemakers, Inc. | Estimate diastolic pressure |
WO2018071715A1 (en) | 2016-10-13 | 2018-04-19 | Masimo Corporation | Systems and methods for patient fall detection |
US11504058B1 (en) | 2016-12-02 | 2022-11-22 | Masimo Corporation | Multi-site noninvasive measurement of a physiological parameter |
US10750984B2 (en) | 2016-12-22 | 2020-08-25 | Cercacor Laboratories, Inc. | Methods and devices for detecting intensity of light with translucent detector |
US10721785B2 (en) | 2017-01-18 | 2020-07-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US10388120B2 (en) | 2017-02-24 | 2019-08-20 | Masimo Corporation | Localized projection of audible noises in medical settings |
WO2018156648A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | Managing dynamic licenses for physiological parameters in a patient monitoring environment |
US10327713B2 (en) | 2017-02-24 | 2019-06-25 | Masimo Corporation | Modular multi-parameter patient monitoring device |
WO2018156804A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | System for displaying medical monitoring data |
WO2018156809A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | Augmented reality system for displaying patient data |
US11086609B2 (en) | 2017-02-24 | 2021-08-10 | Masimo Corporation | Medical monitoring hub |
CN110891486A (en) | 2017-03-10 | 2020-03-17 | 梅西莫股份有限公司 | Pneumonia screening instrument |
WO2018194992A1 (en) | 2017-04-18 | 2018-10-25 | Masimo Corporation | Nose sensor |
US10918281B2 (en) | 2017-04-26 | 2021-02-16 | Masimo Corporation | Medical monitoring device having multiple configurations |
USD835283S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835284S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835282S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
EP3614909B1 (en) | 2017-04-28 | 2024-04-03 | Masimo Corporation | Spot check measurement system |
USD835285S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
WO2018208616A1 (en) | 2017-05-08 | 2018-11-15 | Masimo Corporation | System for pairing a medical system to a network controller by use of a dongle |
US11026604B2 (en) | 2017-07-13 | 2021-06-08 | Cercacor Laboratories, Inc. | Medical monitoring device for harmonizing physiological measurements |
USD890708S1 (en) | 2017-08-15 | 2020-07-21 | Masimo Corporation | Connector |
USD906970S1 (en) | 2017-08-15 | 2021-01-05 | Masimo Corporation | Connector |
US10637181B2 (en) | 2017-08-15 | 2020-04-28 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
US11045163B2 (en) | 2017-09-19 | 2021-06-29 | Ausculsciences, Inc. | Method of detecting noise in auscultatory sound signals of a coronary-artery-disease detection system |
WO2019071050A2 (en) | 2017-10-04 | 2019-04-11 | Ausculsciences, Inc. | Auscultatory sound-or-vibration sensor |
EP4039177A1 (en) | 2017-10-19 | 2022-08-10 | Masimo Corporation | Display arrangement for medical monitoring system |
US11284827B2 (en) | 2017-10-21 | 2022-03-29 | Ausculsciences, Inc. | Medical decision support system |
USD925597S1 (en) | 2017-10-31 | 2021-07-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
EP3703566B1 (en) | 2017-10-31 | 2023-07-26 | Masimo Corporation | System for displaying oxygen state indications |
US11766198B2 (en) | 2018-02-02 | 2023-09-26 | Cercacor Laboratories, Inc. | Limb-worn patient monitoring device |
WO2019204368A1 (en) | 2018-04-19 | 2019-10-24 | Masimo Corporation | Mobile patient alarm display |
WO2019209915A1 (en) | 2018-04-24 | 2019-10-31 | Cercacor Laboratories, Inc. | Easy insert finger sensor for transmission based spectroscopy sensor |
US11627919B2 (en) | 2018-06-06 | 2023-04-18 | Masimo Corporation | Opioid overdose monitoring |
US10779098B2 (en) | 2018-07-10 | 2020-09-15 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US11872156B2 (en) | 2018-08-22 | 2024-01-16 | Masimo Corporation | Core body temperature measurement |
US11389093B2 (en) | 2018-10-11 | 2022-07-19 | Masimo Corporation | Low noise oximetry cable |
US11406286B2 (en) | 2018-10-11 | 2022-08-09 | Masimo Corporation | Patient monitoring device with improved user interface |
USD999246S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
JP7128960B2 (en) | 2018-10-11 | 2022-08-31 | マシモ・コーポレイション | Patient connector assembly with vertical detent |
USD917564S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD916135S1 (en) | 2018-10-11 | 2021-04-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917550S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD998630S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD998631S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
AU2019357721A1 (en) | 2018-10-12 | 2021-05-27 | Masimo Corporation | System for transmission of sensor data using dual communication protocol |
US11464410B2 (en) | 2018-10-12 | 2022-10-11 | Masimo Corporation | Medical systems and methods |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
US11684296B2 (en) | 2018-12-21 | 2023-06-27 | Cercacor Laboratories, Inc. | Noninvasive physiological sensor |
US11701043B2 (en) | 2019-04-17 | 2023-07-18 | Masimo Corporation | Blood pressure monitor attachment assembly |
USD919094S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Blood pressure device |
USD921202S1 (en) | 2019-08-16 | 2021-06-01 | Masimo Corporation | Holder for a blood pressure device |
USD919100S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Holder for a patient monitor |
USD917704S1 (en) | 2019-08-16 | 2021-04-27 | Masimo Corporation | Patient monitor |
USD985498S1 (en) | 2019-08-16 | 2023-05-09 | Masimo Corporation | Connector |
US11832940B2 (en) | 2019-08-27 | 2023-12-05 | Cercacor Laboratories, Inc. | Non-invasive medical monitoring device for blood analyte measurements |
USD927699S1 (en) | 2019-10-18 | 2021-08-10 | Masimo Corporation | Electrode pad |
KR20220083771A (en) | 2019-10-18 | 2022-06-20 | 마시모 코오퍼레이션 | Display layouts and interactive objects for patient monitoring |
CA3157995A1 (en) | 2019-10-25 | 2021-04-29 | Cercacor Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
EP4104037A1 (en) | 2020-02-13 | 2022-12-21 | Masimo Corporation | System and method for monitoring clinical activities |
US11879960B2 (en) | 2020-02-13 | 2024-01-23 | Masimo Corporation | System and method for monitoring clinical activities |
US20210290177A1 (en) | 2020-03-20 | 2021-09-23 | Masimo Corporation | Wearable device for monitoring health status |
USD933232S1 (en) | 2020-05-11 | 2021-10-12 | Masimo Corporation | Blood pressure monitor |
USD979516S1 (en) | 2020-05-11 | 2023-02-28 | Masimo Corporation | Connector |
USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
USD946596S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD946597S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD946598S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD997365S1 (en) | 2021-06-24 | 2023-08-29 | Masimo Corporation | Physiological nose sensor |
USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368283B1 (en) * | 2000-09-08 | 2002-04-09 | Institut De Recherches Cliniques De Montreal | Method and apparatus for estimating systolic and mean pulmonary artery pressures of a patient |
US7689283B1 (en) * | 2004-11-15 | 2010-03-30 | Pacesetter, Inc. | Diastolic mechanical algorithm for optimization of AV timing using a plurality of sensors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850014B1 (en) * | 1995-08-10 | 2003-04-16 | Pentavox Kft. | Apparatus for measuring fetal heart rate |
US6050950A (en) | 1996-12-18 | 2000-04-18 | Aurora Holdings, Llc | Passive/non-invasive systemic and pulmonary blood pressure measurement |
-
2004
- 2004-04-16 CA CA002464634A patent/CA2464634A1/en not_active Abandoned
-
2005
- 2005-04-15 US US11/578,462 patent/US7909772B2/en active Active
- 2005-04-15 WO PCT/CA2005/000568 patent/WO2005099562A1/en active Application Filing
- 2005-04-15 CA CA002569730A patent/CA2569730A1/en not_active Abandoned
- 2005-04-15 JP JP2007507636A patent/JP2007532207A/en not_active Withdrawn
- 2005-04-15 EP EP05734306A patent/EP1744666A1/en not_active Withdrawn
-
2011
- 2011-03-21 US US13/053,202 patent/US20120071767A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368283B1 (en) * | 2000-09-08 | 2002-04-09 | Institut De Recherches Cliniques De Montreal | Method and apparatus for estimating systolic and mean pulmonary artery pressures of a patient |
US7689283B1 (en) * | 2004-11-15 | 2010-03-30 | Pacesetter, Inc. | Diastolic mechanical algorithm for optimization of AV timing using a plurality of sensors |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184315A1 (en) * | 2012-06-05 | 2013-12-12 | 3M Innovative Properties Company | Enhanced auscultatory sensor and analysis for patient diagnosis |
US9521956B2 (en) | 2012-06-05 | 2016-12-20 | 3M Innovative Properties Company | Enhanced auscultatory sensor and analysis for patient diagnosis |
Also Published As
Publication number | Publication date |
---|---|
EP1744666A1 (en) | 2007-01-24 |
CA2464634A1 (en) | 2005-10-16 |
US7909772B2 (en) | 2011-03-22 |
JP2007532207A (en) | 2007-11-15 |
CA2569730A1 (en) | 2005-10-27 |
WO2005099562B1 (en) | 2006-03-16 |
WO2005099562A1 (en) | 2005-10-27 |
US20080091115A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120071767A1 (en) | Pulmonary artery pressure estimator | |
Choudhary et al. | Automatic detection of aortic valve opening using seismocardiography in healthy individuals | |
US6048319A (en) | Non-invasive acoustic screening device for coronary stenosis | |
US5533511A (en) | Apparatus and method for noninvasive blood pressure measurement | |
RU2195168C2 (en) | Equipment and method for supervision of characteristics of cardiac activity | |
US7771364B2 (en) | Method and system for cardiovascular system diagnosis | |
US9706952B2 (en) | System for ventricular arrhythmia detection and characterization | |
US20070021673A1 (en) | Method and system for cardiovascular system diagnosis | |
US20030093002A1 (en) | Function indicator for autonomic nervous system based on phonocardiogram | |
Zhang et al. | Sound based heart rate monitoring for wearable systems | |
US6616608B2 (en) | Periodic-physical-information measuring apparatus | |
Singla et al. | Cuff-less blood pressure measurement using supplementary ECG and PPG features extracted through wavelet transformation | |
EP0960598B1 (en) | A method and a device for noninvasive measurement of the blood pressure and for detection of arrhythmia | |
White et al. | Analysing heart murmurs using time-frequency methods | |
Samimi et al. | Cuffless blood pressure estimation using cardiovascular dynamics | |
Prabhu et al. | A novel approach for non-invasive measurement of mean arterial pressure using pulse transit time | |
Singh et al. | Hilbert vibration decomposition of seismocardiogram for hr and hrv estimation | |
US20170065190A1 (en) | Sensor for ventricular and outflow tract obstruction | |
Mann et al. | Exploring the impact of sensor location on seismocardiography-derived cardiac time intervals | |
Lui et al. | A novel calibration procedure of pulse transit time based blood pressure measurement with heart rate and respiratory rate | |
Anisimov et al. | Comparison of heart rate derived from ECG and pulse wave signals during controlled breathing test for biofeedback systems | |
Akbulut et al. | Estimation of Beat-to-Beat Interval from Wearable Photoplethysmography Sensor on Different Measurement Sites During Daily Activities | |
Manimegalai et al. | Wavelet Based Cardiovascular Parameters Estimation System from ECG and PPG Signals | |
Guedes et al. | Heart sound analysis for blood pressure estimation | |
US20220361798A1 (en) | Multi sensor and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |